Ligand id: 1133

Name: liraglutide

Structure and Physico-chemical Properties

2D Structure
1. Bray GA. (2015)
Obesity: Liraglutide--another weapon in the war against obesity?.
Nat Rev Endocrinol, 11 (10): 569-70. [PMID:26260142]
2. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H. (2000)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.
J Med Chem, 43: 1664-1669. [PMID:10794683]
3. Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, O'Neill C. (2013)
The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
Neuromolecular Med., 15 (1): 102-14. [PMID:23011726]
4. McClean PL, Gault VA, Harriott P, Hölscher C. (2010)
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
Eur. J. Pharmacol., 630 (1-3): 158-62. [PMID:20035739]